Anti-PD 1 Brain Collaboration + Radiotherapy Extension Study

The ABC-X study, a multicentre investigator-initiated trial sponsored by Melanoma Institute Australia, is a phase II trial, randomised and open label of ipilimumab and nivolumab with concurrent intracranial stereotactic radiotherapy versus ipilimumab and nivolumab alone in patients with melanoma brain metastases.